Abstract | BACKGROUND: There is a need for the development of novel nonsteroidal topical drugs for the treatment of atopic dermatitis (AD). OBJECTIVES: The primary objective was to evaluate the efficacy of WBI-1001 over 6 weeks of treatment of mild to severe AD. METHODS: Patients with AD affecting 3-20% of their body surface area and with an Investigator's Global Assessment ( IGA) of 2-4 were randomized (1 : 1 : 1) to receive placebo, WBI-1001 0·5% or WBI-1001 1·0% in a cream formulation applied twice daily for 6 weeks. At the end of this phase, patients receiving WBI-1001 continued the same treatment for an additional 6 weeks. Patients receiving placebo entered into a 6-week double-blind phase with re-randomization (1 : 1) to WBI-1001 0·5% or 1·0% cream. The primary objective was to evaluate the efficacy of WBI-1001 over 6 weeks of treatment of mild to severe AD. The primary endpoint was the mean change from baseline in IGA at day 42 (week 6). RESULTS: In total, 148 patients were randomized and analysed in the placebo (51), WBI-1001 0·5% (50) and WBI-1001 1·0% (47) groups. There was a decrease of 1·3 [43%; P < 0·001; 95% confidence interval (CI) -1·2 to -0·5] and 1·8 (56·3%; P < 0·001; 95% CI -1·6 to -0·9) in IGA at day 42 in the WBI-1001 0·5% and 1·0% groups, respectively, as compared with a decrease of 0·5 (14·7%) in the placebo group. Adverse drug reactions included a few cases of folliculitis and contact dermatitis. CONCLUSIONS:
WBI-1001 is an efficacious novel topical anti-inflammatory molecule for the treatment of AD.
|
Authors | R Bissonnette, Y Poulin, Y Zhou, J Tan, H C Hong, J Webster, W Ip, L Tang, M Lyle |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 166
Issue 4
Pg. 853-60
(Apr 2012)
ISSN: 1365-2133 [Electronic] England |
PMID | 22182053
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011. |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Ointments
- Resorcinols
- Stilbenes
- tapinarof
|
Topics |
- Administration, Cutaneous
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage, adverse effects)
- Chronic Disease
- Dermatitis, Atopic
(drug therapy)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Eczema
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Ointments
- Resorcinols
(administration & dosage, adverse effects)
- Severity of Illness Index
- Stilbenes
(administration & dosage, adverse effects)
- Treatment Outcome
- Young Adult
|